Director/PDMR Shareholding

RNS Number : 0581Z
Hemogenyx Pharmaceuticals PLC
19 May 2021
 

19 May 2021

 

Hemogenyx Pharmaceuticals plc 

("Hemogenyx Pharmaceuticals" or the "Company")

 

Director/PDMR Shareholding

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has been notified that Andrew Wright, the Company's Financial Controller and Company Secretary (PDMR), has purchased 1,088,120 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at an average price of 1.8288 pence per share. Following this transaction, Mr Wright has a total beneficial interest in 2,715,111 Ordinary Shares, representing approximately 0.50 per cent of the Company's issued share capital.

 

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

 

1.

Details of PDMR/person closely associated with them ("PCA")

a)

Name

Andrew Wright

b)

Position/status

PDMR: Financial Controller and Company Secretary

c)

Initial notification/
amendment

Initial notification

2.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Ordinary shares of Hemogenyx Pharmaceuticals plc
Identification code GB00BYX3WZ24

b)

Nature of the transaction

Standalone acquisition of shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

GBP £0.018288

1,088,120



d)

Aggregated information

Aggregated volume

Price

Price(s)

Volume(s)

GBP £19,899.54

1,088,120

e)

Date of the transaction

2021-05-18

f)

Place of the transaction

London Stock Exchange
XLON

 

 

Enquiries:

 

Hemogenyx Pharmaceuticals plc

https://hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

headquarters@hemogenyx.com

Peter Redmond, Director

peter.redmond@hemogenyx.com





SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Adam Cowl







Peterhouse Capital Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow







 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBRGDUDUBDGBI
UK 100